- Research article
- Open Access
Amyloid beta protein-induced zinc sequestration leads to synaptic loss via dysregulation of the ProSAP2/Shank3 scaffold
Molecular Neurodegeneration volume 6, Article number: 65 (2011)
Memory deficits in Alzheimer's disease (AD) manifest together with the loss of synapses caused by the disruption of the postsynaptic density (PSD), a network of scaffold proteins located in dendritic spines. However, the underlying molecular mechanisms remain elusive. Since it was shown that ProSAP2/Shank3 scaffold assembly within the PSD is Zn2+-dependent and that the amyloid beta protein (Aβ) is able to bind Zn2+, we hypothesize that sequestration of Zn2+ ions by Aβ contributes to ProSAP/Shank platform malformation.
To test this hypothesis, we designed multiple in vitro and in vivo assays demonstrating ProSAP/Shank dysregulation in rat hippocampal cultures following Aβ oligomer accumulation. These changes were independent from alterations on ProSAP/Shank transcriptional level. However, application of soluble Aβ prevented association of Zn2+ ions with ProSAP2/Shank3 in a cell-based assay and decreased the concentration of Zn2+ clusters within dendrites. Zn2+ supplementation or saturation of Aβ with Zn2+ ions prior to cell treatment was able to counter the effects induced by Aβ on synapse density and ProSAP2/Shank3 levels at the PSD. Interestingly, intracellular Zn2+ levels in APP-PS1 mice and human AD hippocampus are reduced along with a reduction in synapse density and synaptic ProSAP2/Shank3 and Shank1 protein levels.
We conclude that sequestration of Zn2+ ions by Aβ significantly contributes to changes in ProSAP2/Shank3 platforms. These changes in turn lead to less consolidated (mature) synapses reflected by a decrease in Shank1 protein levels at the PSD and decreased synapse density in hippocampal neurons.
The loss of synapses is closely associated with the cognitive impairment seen in patients with Alzheimer's disease (AD) [1–3]. Recent findings suggest that this loss is mediated by increasing levels of amyloid beta protein (Aβ), a product of amyloid precursor protein (APP) metabolism [4–6], although the mechanisms through which Aβ accumulation finally leads to synaptic degeneration are not fully understood. However, Pham et al. have recently shown that Aβ oligomers progressively accumulate in brains of AD patients as well as in APP transgenic mice together with a reduction in the levels of synaptic scaffold proteins such as Shank1 and ProSAP2/Shank3 .
Proteins of the ProSAP/Shank (Synamon, CortBP, Spank, SSTRIP) family play a crucial role in proper synapse function  and have been linked to autism, schizophrenia and AD [7–13]. Treatment of rat frontocortical neurons with soluble Aβ1-40 resulted in a significant thinning of the PSD and in decreased synaptic levels of Shank1  and other ProSAP/Shank platform-associated PSD proteins such as PSD-95 , Homer  and GKAP/SAPAP . Although the precise mechanism of ProSAP/Shank scaffold protein dysregulation still remains unclear, an emerging model is that alterations in those proteins could interfere with cognitive function and behavior by impairing excitatory glutamatergic synapses.
ProSAP/Shank platforms are organized through Zn2+-ions [16–18] and ProSAP/Shank protein levels depend on the local Zn2+ concentration and influx . Zn2+ is found in PSDs and in synaptic vesicles at glutamatergic synapses throughout the neocortex and hippocampus and is released during synaptic activity . Intriguingly, high concentrations of Zn2+ are also observed in neuritic plaques and cerebrovascular amyloid deposits from both AD patients and AD-prone transgenic mice [20–22]. Aβ is a metal-binding protein with high affinity for copper and zinc [23, 24] and Zn2+ ions promote Aβ oligomerization .
In our study, we show that soluble oligomers of Aβ1-40 and Aβ1-42 induce changes in ProSAP/Shank protein levels at the synapse. These changes are not caused by a reduced ProSAP/Shank gene expression, but reflect an altered localization of ProSAP/Shank family members. Aβ seems to efficiently compete with Zn2+ loading of ProSAP2/Shank3 finally leading to a decrease in dendritic Zn2+ signals. The decline in synapse density and ProSAP2/Shank3 levels can be rescued by supplementation with Zn2+-ions or saturation of Aβ with Zn2+. Furthermore, in APP-PS1 mice and human AD brain sections, Zn2+ sequestration in senile plaques is accompanied by a decrease in intracellular Zn2+ concentration along with a decrease in synapse density and synaptic ProSAP2/Shank3 and Shank1 protein levels.
Thus, our results lead to a model illustrating that Aβ pathology is at least in part caused by trapping synaptic Zn2+ in Aβ complexes, preventing Zn2+ from reaching its postsynaptic targets like ProSAP/Shank proteins, ultimately leading to a dysregulation of the postsynaptic scaffold and subsequent loss of synapses which might in turn lead to the observed cognitive deficits in AD.
Soluble Aβ oligomers induce changes in synapse density, maturation state and synaptic ProSAP2/Shank3 and Shank1 protein levels in primary hippocampal neurons
Based on recent data showing that Aβ induces the disruption of the Homer1b and Shank1 scaffold , we investigated if soluble Aβ oligomers are sufficient to induce changes in ProSAP/Shank family members. We applied 1 μM Aβ1-40 or Aβ1-42 to rat primary hippocampal cell culture neurons (DIV15-17) and fixed them after 1, 3, 6 and 24 h, respectively. Immunohistochemistry was performed using anti-ProSAP2/Shank3 and anti-Shank1 antibodies co-stained with an anti-Bassoon antibody as a presynaptic marker. Synapse density was calculated by measuring the number of synapses (Bassoon and ProSAP/Shank positive sites) per unit dendrite length. The mean synapse density was significantly decreased after 6-24 h exposure to Aβ1-40, leading to a 30% reduction in synapse density after 24 h (Figure 1A and Aβ1-42, Additional file 1A).
To assess the maturation state of synapses, we characterized the morphology of dendritic spines in Aβ-treated cultures (Figure 1B). The results show that the proportion of "filopodia like" and "thin" spines, representing immature synapses with respect to the total synapse number, increased after 24 h Aβ treatment compared to control conditions (Figure 1B). This shift towards immature spines was accompanied by a decrease of mature ("mushroom and stubby") spines.
ProSAP/Shank family members are recruited to synapses in a sequential and development-dependent manner  beginning with ProSAP1/Shank2 that becomes concentrated at the sites where PSDs are thought to form , followed by ProSAP2/Shank3 protein. Finally, with sufficient amount of ProSAP1/Shank2 and ProSAP2/Shank3 present at the synapse, the clustering of Shank1 leads to maturation of the synaptic contacts and to spines with a mushroom-like appearance . Hence, a shift towards immature spines should also influence the levels of Shank1 at synapses and we therefore measured the mean grey value and mean area of ProSAP2/Shank3 and Shank1 signals opposite to Bassoon signals (Figure 1C). In hippocampal neurons, ProSAP2/Shank3 and Shank1 proteins were significantly downregulated at the synapse after 24 h treatment with Aβ1-40 (18% ± 2% and 30 ± 7%, respectively; Aβ1-42, Additional file 1B) along with a downregulation of Homer1 and PSD-95 (Additional file 1C). The protein levels of Bassoon were not significantly affected (Figure 1C). A similar decrease was observed in cortical neurons, however here, a downregulation occurred as early as 1 h after treatment as reported previously  (Additional file 1D). The observed changes were caused by a decrease of protein levels at the synapse since the mean signal area was unaffected after Aβ treatment (Additional file 1E). Cumulative histograms illustrate that the puncta intensity values are shifted across the entire populations of ProSAP2/Shank3 and Shank1 puncta, revealing that mature synapses were affected by the treatment similarly to immature synapses (Additional file 1F). We thus conclude that exposure of neurons to Aβ causes the loss of synapses and that decreased ProSAP2/Shank3 and Shank1 levels following Aβ application, lead to altered maturation states of excitatory synapses.
Aβ1-40oligomer-induced changes in ProSAP/Shank protein levels are not mediated via transcriptional regulation
The changes in synaptic ProSAP/Shank levels after exposure to Aβ1-40 (1 μM) in vitro could further be confirmed by Western Blotting of P2 membrane fractions from hippocampal neurons at 15 DIV after Aβ-treatment for 6 and 24 h. Compared to untreated cells (time-point 0), significantly lower levels of ProSAP2/Shank3 (6 and 24 h) and Shank1 (24 h) within the P2 fraction of lysates could be detected after 24 h of Aβ1-40 treatment - similar to the effect observed by grey value measurement of immunohistochemical ProSAP2/Shank3 and Shank1 signals at the synapse (Figure 2A, for comparison see Figure 1C). After 24 h of treatment, Homer1 also showed a significant decrease in protein levels and PSD-95 a clear trend towards downregulation (Figure 2A, β-III Tubulin was used as control).
To assess if the observed changes in ProSAP/Shank protein levels at synapses were due to changes in gene expression levels, we performed quantitative RT-PCR (Figure 2B). Hippocampal neurons (DIV15) were treated with Aβ1-40 and mRNA was extracted after 1, 6, and 24 h. The results showed no significant differences in gene expression levels compared to controls indicating that the observed changes are due to a structural alteration of the PSD scaffold leading to a shift of ProSAP2/Shank3 from a PSD bound state to a soluble pool. Indeed, the ratio between ProSAP2/Shank3 within the S2 soluble (Additional file 2A) and P2 membrane (Figure 2A) fraction set to 1 at time-point 0 rises to 1.59 at 6 h and 1.69 at 24 h after treatment with Aβ. This is underlined by data showing that the reduction of ProSAP2/Shank3 and Shank1 at the synapse is independent of both, proteasomal degradation and protein synthesis, since treatment with the proteasome inhibitor MG132 or protein synthesis inhibitor cycloheximide (CHX) did not prevent Aβ1-40-induced changes in synaptic signal intensities of ProSAP2/Shank3 and Shank1. However, MK801, an NMDAR antagonist, significantly decreased the amount of Aβ1-40-induced changes in Shank1 levels as shown before  (Additional file 2B).
Zinc sequestration by Aβ influences ProSAP2/Shank3 Zn2+ loading and leads to lower intracellular Zn2+levels in hippocampal neurons
Since ProSAP2/Shank3 protein levels at the PSD are sensitive to the local Zn2+ concentration  and Aβ has a Zn2+-binding site and might thus be able to sequester Zn2+ ions, we investigated if Aβ is indeed able to sequester extracellular Zn2+ ions affecting the Zn2+ loading of ProSAP2/Shank3. To that end, we transfected Cos7 cells growing in 5 μM Zn2+-supplemented medium with GFP-ProSAP2/Shank3 and depleted Zn2+-ions using TPEN (Figure 3A). After Zn2+ depletion, Zn2+ ions were introduced back into the medium via ZnCl2 with and without additional Aβ treatment. Furthermore, as a control, Aβ was preloaded with Zn2+ ions and then added to the medium followed by ZnCl2 application. For these experiments, we took advantage of a dye (Zinquin) that fluoresces when it binds Zn2+  to measure the local Zn2+ concentration (correlating with Zinquin signal intensity) colocalizing with GFP-ProSAP2/Shank3 clusters. The results show that in control cells, GFP-ProSAP2/Shank3 colocalizes with Zn2+ (Figure 3A, t = 0 min, B). After 10 min application of the Zn2+ chelator TPEN, Zn2+-ions were efficiently removed from ProSAP2/Shank3 clusters (Figure 3A, t = 10 min, B,C). Supplementation with 10 μM ZnCl2 restored and increased the initial Zn2+ association of ProSAP2/Shank3 (Figure 3A left panel t = 50 min, B,C). However, 20 min application of 10 μM Aβ1-40 (red fluorescence) followed by supplementation of the medium with 10 μM ZnCl2 for 20 min only resulted in a minor increase in Zn2+ loading of ProSAP2/Shank3 (Figure 3A, middle panel t = 50 min, B,C). In contrast, preloading of 10 μM Aβ1-40 (red fluorescence) with 10 μM ZnCl2 followed by supplementation of the medium with 10 μM ZnCl2, led to a significantly higher increase in ProSAP2/Shank3 Zn2+ loading (Figure 3A, right panel, t = 50 min, B,C). Thus, Aβ influences Zn2+ loading of ProSAP2/Shank3 by sequestering extracellular Zn2+-ions. Because Zn2+-ions pass through the extracellular space into the postsynaptic compartment after activity-dependent vesicle release, it could well be that Aβ oligomers accumulating in the synaptic cleft interfere with this process.
As the observed changes in synapse density and synaptic levels of ProSAP/Shank within 6-24 h after treatment with Aβ are relatively fast, we followed the possibility that intracellular Aβ contributes to a dysregulation of intracellular Zn2+ levels in neurons. Indeed, application of fluorescently-tagged Aβ to hippocampal neurons in cell culture was followed by intracellular colocalization of Aβ and Zn2+ (Figure 4A, arrows). Since these neurons were cultivated in medium without Zn2+-supplementation, Zn2+ ions colocalizing with Aβ are most likely depleting other Zn2+ stores. We therefore investigated postsynaptic Zn2+ levels of hippocampal neurons after treatment with Aβ Zinquin labels postsynaptic Zn2+ (Additional file 3A), which is in line with previous studies that revealed a striking colocalization of dendritic ProSAP2/Shank3 and Zinquin, colocalizing apposed to presynaptic boutons loaded with the styryl dye FM . A significant reduction of Zn2+ signals within dendrites (Figure 4B and Additional file 3B) was seen after Aβ treatment.
Zn2+supplementation leads to a rescue of Aβ induced decrease in synapse density and ProSAP2/Shank3 levels at the synapse
Based on the results obtained through the previous experiments, we investigated if Zn2+ supplementation along with Aβ1-40 treatment or the saturation of Aβ1-40 with Zn2+ before treatment led to a rescue of the observed changes in synapse density and ProSAP2/Shank3 protein levels at the PSD. Therefore, hippocampal neurons (DIV15) were treated with Aβ1-40 and supplemented with equimolar levels of ZnCl2 or with equimolar ZnCl2 preincubated with Aβ1-40 (Figure 5). Synapse density and protein levels of ProSAP2/Shank3 at the synapse were measured as described above (Figure 1). The results show that after treatment for 1, 6 and 24 h, neither control (DMSO-supplemented) nor 1 μM Zn2+-supplemented neurons display an increase or decrease in synapse density (Figure 5A, B). However, treatment with 1 μM Aβ1-40 resulted in a significant decrease of synapse density after 6 and 24 h (Figure 5A). In contrast, treatment of hippocampal neurons with 1 μM Aβ1-40 preincubated for 1 h on ice with 1 μM ZnCl2 led to a significantly higher synapse density compared to treatment with 1 μM Aβ1-40 after 6 and 24 h. Saturation of Aβ with Zn2+ thus ameliorates the effects of Aβ on synapse density. To investigate, if supplementation of Zn2+ after Aβ-induced decrease in synapse density can rescue the effects of Aβ we treated hippocampal neurons (DIV15) for 18 h with 1 μM or 10 μM Aβ1-40, followed by 1 μM or 10 μM ZnCl2 supplementation for 6 h, respectively (Figure 5B). ZnCl2 supplementation for 6 h alone did not induce changes in synapse density, whereas 1 μM Aβ1-40 treatment resulted in a significant reduction after 18 and 24 h. However, supplementation of ZnCl2 for 6 h after 18 h treatment with Aβ1-40, led to a significantly higher synapse density compared to cells treated with Aβ1-40 alone. In fact, the synapse density after ZnCl2 supplementation was not significantly different from control (DMSO-treated) cells (Figure 5B).
To assess if Zn2+ supplementation or saturation of Aβ with Zn2+ is able to rescue ProSAP2/Shank3 levels at the synapse, we measured ProSAP2/Shank3 signal grey values under the conditions described above and performed Western Blot analysis of protein levels. The results show that after treatment for 1, 6 and 24 h, neither control (DMSO-supplemented) nor 1 μM Zn2+-supplemented neurons display any changes in ProSAP2/Shank3 levels at the synapse (Figure 5C, D, for loading control of Figure 5D see Additional file 4A). Treatment with 1 μM Aβ1-40 resulted in a significant decrease of ProSAP2/Shank3 levels after 6 and 24 h (Figure 5C) compared to control (DMSO treated) cells. However, 24 h treatment of hippocampal neurons with 1 μM Aβ1-40 preincubated for 1 h on ice with 1 μM ZnCl2 led to significantly higher ProSAP2/Shank3 levels compared to treatment with 1 μM Aβ1-40 alone (Figure 5C, E). Thus, Zn2+-saturated Aβ causes less decrease of ProSAP2/Shank3 protein levels at the synapse. Similar to the experiments described above, we investigated if supplementation of Zn2+ after Aβ protein induced decrease in ProSAP2/Shank3 levels is able to rescue the effects of Aβ. To that end, we treated hippocampal neurons (DIV15) for 18 h with 1 μM or 10 μM Aβ1-40, followed by 1 μM or 10 μM ZnCl2 supplementation for 6 h (Figure 5D, E). Zn2+ supplementation for 6 h alone did not induce changes in ProSAP2/Shank3 levels, whereas 1 μM Aβ1-40, treatment resulted in a significant reduction. Supplementation of 1 μM or 10 μM ZnCl2 for 6 h after 18 h treatment with 1 μM or 10 μM Aβ1-40 respectively, led to a complete rescue of the decrease in ProSAP2/Shank3 levels (Figure 5D, E) and did not depend on enhanced protein synthesis (Additional file 4B). Interestingly, Zn2+ supplementation was also able to rescue synaptic Shank1 and partially, although not significantly, synaptic Homer1 levels (Additional file 4C).
Previous studies have demonstrated that the Aβ-Zn2+ binding site is localized within residues 6-28 and that histidines may serve as the principal sites of interaction , but interaction of Zn2+ with the full-length Aβ1-40 and Aβ1-42, as well as the truncated Aβ1-16 and Aβ1-28, were reported . Thus, we used Aβ29-40 as a control in our assays, because the C-terminus residues 29-40 do not seem to be affected by metal ion interactions . The results showed that Aβ29-40 does not significantly reduce synapse density within 24 h of treatment (Additional file 4D) nor does it significantly affect synaptic ProSAP2/Shank3 levels (Additional file 4E). We also investigated the amount of cell death after Aβ1-40, Aβ1-42 and Aβ29-40 treatment. Our data show similar toxicity with respect to cell death in hippocampal cell cultures. For example, at 48 h, Aβ1-40, Aβ1-42 and Aβ29-40-treated cells showed signs of cell death (Additional file 4F), while no significant decrease in neuron number was seen after 24 h of treatment. This implies that cell death occurs independently from Zn2+ dysregulation.
Altered Zn2+and ProSAP/Shank levels in human AD and APP-PS1 mouse brain
To assess whether an excess of Aβ leads to alterations of Zn2+ levels in vivo, we visualized Zn2+ using Zinpyr-1 in hippocampal brain sections of APP-PS1 mice (3, 6 and 12 months of age) and AD patients. The brightness of the intracellular Zinpyr-1 fluorescence that correlates with local Zn2+ levels, was assessed (Figure 6A, 7A), as was the specificity of the signal by application of the Zn2+ chelator TPEN (Additional file 5). After treatment with TPEN, the Zinpyr-1 signals in the CA3/dentate gyrus regions of the hippocampus were eliminated (Additional file 5). A comparison of Zn2+ levels in the dentate gyrus and CA3 regions (Additional file 6) of wild type and APP-PS1 mice revealed a significantly lower Zn2+ staining in APP-PS1 mice beginning with 6 m.o.a. (Figure 6A). Moreover, extracellular Zn2+ ions were enriched in plaques formed by Aβ (Figure 6A, arrows). These data are consistent with higher Aβ levels causing a depletion of Zn2+ in the hippocampus of older APP-PS1 mice. To assess whether disease progression in APP-PS1 mice is associated with a reduction in synapse density and/or synaptic ProSAP/Shank levels, we stained hippocampal sections from APP-PS1 mice with antibodies against ProSAP2/Shank3 or Shank1 as well as Bassoon and VGluT. In these experiments, we observed a significant reduction in synapse density in brain sections of APP-PS1 mice at 12 m.o.a. (Figure 6B, C). Similarly, synaptic levels of ProSAP2/Shank3 and Shank1 were significantly decreased at this age (Figure 6B, D).
To assess whether patients with Alzheimer's Disease (AD) exhibit similar reductions in Zn2+ and ProSAP/Shank levels in the hippocampus, we analyzed brain sections from 14 control and AD patients (Table 1). Human sections were divided into three groups based on their Clinical Dementia Rating (CDR), Mini-Mental State Examination (MMSE), and Braak scores: a) "control" sections, b) sections of patients with mild cognitive impairment "MCI" and c) patients with terminal/severe Alzheimer's disease "AD". Similar to the experiments conducted in APP-PS1 mice, we assessed intracellular Zn2+ concentration using Zinpyr-1 staining. The results show that sections from severely impaired AD patients ("AD") display significantly lower Zn2+ staining (Figure 7A). Moreover, extracellular Zn2+ ions were enriched at plaques formed by Aβ (Figure 7B, arrows). These observations are again consistent with the capacity of Aβ to bind, sequester and thus reduce intracellular Zn2+ levels in the hippocampus of AD patients.
To assess synapse density, we initially stained human hippocampal sections with antibodies against the presynaptic active zone protein Bassoon and the PSD protein Homer1. The number of Bassoon and Homer1 colocalizing puncta was then quantified per optic field (Figure 8A). This revealed a significant reduction in synapse number in brain sections of severe AD cases ("AD") compared to controls. To measure the change of ProSAP2/Shank3 and Shank1 at these synapses, the signal intensity of Alexa568-labeled ProSAP/Shank proteins opposed to a Bassoon or VGluT signal was measured (Figure 8B). Ten optical fields of 3 different sections per case were measured and the mean grey value per group calculated. The results showed a significant reduction of ProSAP2/Shank3 and Shank1 in the AD group compared to controls. Moreover, the clear trend towards this reduction could already be seen in "MCI" patient sections.
Soluble Aβ oligomers are thought to cause early synaptic damage and memory deficits in AD , although the mechanisms through which Aβ aggregates might lead to this phenotype are not yet fully understood. During the progression of AD, monomers of Aβ can aggregate to form amyloid fibrils. Five distinct fibrillar aggregates induced by Zn2+ have been described , including protofibrils, Aβ-derived diffusible ligands (ADDL) and oligomeric species [34, 35]. Oligomeric Aβ peptides have the ability to form dimers, trimers, tetramers and higher-order arrays that can form so-called annular structures. These are thought to influence the functionality of cytoskeleton-associated proteins, cause damage to synaptic spines and inhibit long-term potentiation in cultured neurons [33, 36, 37] and in vivo . It was shown that physiological levels of Cu2+ and Zn2+ cause Aβ to aggregate  and that Zn2+ ions are bound to Aβ via the histidine imidazole rings within senile plaque cores . Recently, Adlard et al. proposed a mechanism whereby Aβ pathology causes cognitive impairment by trapping synaptic Zn2+ rather than through direct toxicity . Thus, the transsynaptic movement of Zn2+ may be severely compromised in AD by being sequestered in Aβ. This trapping of Zn2+ might mimic ZnT3 ablation  and indeed, mice with a disruption of the vesicular Zn2+ transporter ZnT3, display complete absence of Zn2+ from synaptic vesicles throughout the brain  as well as synaptic and memory deficits comparable to those seen in a cognitively impaired APP transgenic mouse model of AD .
Based on these findings, we propose a model, where Zn2+-ions might fail to reach their postsynaptic targets like ProSAP/Shank proteins due to sequestration by Aβ, leading to a dysregulation of the PSD scaffold and ultimately to a loss of synapses that can also be seen in ProSAP/Shank knockdown conditions . This model is consistent with findings of Deshpande et al., who postulated that sequestration of Zn2+ in oligomeric Aβ leads to reduced availability of Zn2+ at the synapse, ultimately leading to cognitive deficits in AD . To test this model, we investigated the influence of Aβ1-40 and Aβ1-42 on ProSAP/Shank family members in hippocampal neuron culture. In line with a number of recent publications showing the possibility that Aβ oligomers influence synaptic proteins and thus interfere with synaptic function [7, 12, 13, 44, 45], our study shows that the synaptic levels of ProSAP2/Shank3 and Shank1 decrease significantly following the addition of Aβ to primary neurons. Moreover, introduction of Aβ oligomers leads to a significant reduction (about 25%) in synapse density in hippocampal cultures, which is in agreement with previous studies reporting 11 to 77% declines in synaptophysin immunostaining in brain sections [46, 47]. These results are also consistent with recent studies in cellular and rodent models, showing that small soluble oligomers are toxic because they directly damage synapses [32, 48]. Furthermore, our experiments show that the loss of synapses is caused by a decrease in mature synapses. Thus, we conclude that the reduction in synapse density caused by Aβ is due to impaired activity dependent maturation and destabilization of mature synapses, but leaves the ability of an initial formation of synapses intact.
Additionally, treatment of hippocampal neurons with Aβ1-40 leads to a significant downregulation of ProSAP2/Shank3 at the synapse, to an impairment in synapse maturation and, in line with previous studies, to a downregulation of synaptic Shank1 levels . The decrease in synaptic ProSAP2/Shank3 is also reflected by a decrease in protein levels in the P2 fraction as assessed by Western Blotting after 24 h treatment with Aβ1-40. Given the multiple interaction partners of ProSAP/Shank proteins at the synapse, it is likely that Aβ mediated changes in ProSAP/Shank complex formation cause synaptic dysfunction induced by reducing actin cytoskeletal assembly, spine motility as well as the maturation and plasticity of excitatory glutamatergic synapses.
We also show that the observed changes in ProSAP/Shank levels at the synapse are not due to altered gene expression, proteasomal degradation or protein synthesis and it appears that other posttranscriptional mechanisms control synaptic ProSAP/Shank levels. One interesting candidate is Zn2+, which is known to bind and regulate the synaptic localization of specific ProSAP/Shank family members, including ProSAP1/Shank2 and ProSAP2/Shank3 but not Shank1 [16–18]. We thus investigated whether an increased demand on extracellular Zn2+, e.g. by an increased level of Aβ, would reduce cellular levels of Zn2+ and consecutively the synaptic levels of ProSAP/Shank family members. Using a cell-based assay, we directly demonstrated that the presence of extracellular Aβ interferes with the proper loading of ProSAP2/Shank3 with Zn2+. In contrast, saturation of Aβ with Zn2+ before application does not change ProSAP2/Shank3 Zn2+ loading.
In hippocampal cell culture, exogenously applied Aβ clusters with Zn2+ intracellular and treatment of cultured neurons with Aβ reduces dendritic Zn2+ levels. It was demonstrated previously that some intracellular Aβ is derived from extracellular Aβ pools and several distinct pathways of entry for extracellular Aβ have been proposed [49, 50]. Although intracellular accumulation of Aβ is seen in multivesicular bodies and lysosomes, it can also be found within the cytosol . Indeed, Kandimilla et al. have shown that Aβ is internalized by neurons primarily via passive diffusion . That way, a fraction of intracellular accumulating Aβ might directly compete with Zn2+ binding proteins such as ProSAP2/Shank3 for Zn2+ ions in addition to the sequestration of extracellular Zn2+ ions.
Based on these findings, we predicted that supplementation of hippocampal cultures with Zn2+ during the treatment with Aβ or application of Zn2+-saturated Aβ would lead to a rescue of the observed loss-of-ProSAP2/Shank3 phenotype. Our results show that the Aβ-induced decrease in synapse density as well as lowered synaptic levels of ProSAP2/Shank3 can indeed be rescued by Zn2+-supplementation. Moreover, Zn2+ saturated Aβ causes significantly less changes in synapse density and ProSAP2/Shank3 levels. Interestingly, also the decrease of Shank1 that shows a stronger requirement of NMDAR activity compared to ProSAP2/Shank3, can be rescued by Zn2+-supplementation. This indicates that Shank1 scaffold plasticity might depend on both, homeostatic changes via ProSAP2/Shank3 and the presence of Zn2+ ions as well as on changes induced by synaptic activity, driven by the activation of downstream signaling pathways.
Our findings are further supported by in situ studies using APP-PS1 mice and AD patient brain sections. Here, we observed that Zn2+ ions are enriched within amyloid plaques present in the hippocampus of older APP-PS1 mice and patients with severe AD. Intriguingly, intracellular Zn2+ concentrations are ~20% lower in neurons from these sections compared to control sections. However, in addition to the sequestration of Zn2+ by Aβ, other mechanisms may contribute to decreased intracellular Zn2+ concentrations, for example Metallothioneins (MTs) or other Zn2+-binding proteins such as α2 macroglobulin (A2M)  may alter levels by regulating intracellular free Zn2+. MT upregulation, as reported for MT-I in AD mouse models , leads to inhibition of NO-mediated Zn2+ release. Furthermore, pro-inflammatory cytokines cause a large induction of MTs . Several Zn2+ transporter proteins, including ZnT-1, ZnT-4 and ZnT-6, are altered in brain regions of subjects with early and late stages of AD . Moreover, several members of the ZnT family (ZnT-1, 3, 4, 5, 6, 7) are expressed in amyloid plaques .
In addition to reduced intracellular Zn2+ levels, we found a significant decrease in synapse density and synaptic ProSAP2/Shank3 and Shank1 protein levels. While chelation of Zn2+ by extracellular Aβ appears a likely mechanism for influencing Zn2+ levels in the brain, it should be noted that intracellular chelation of Zn2+ might also contribute to its sequestration. Interestingly, it was recently found that serum Zn2+ concentrations were significantly reduced from 12.3 μmol/l to 10.9 μmol/l in AD patients compared to control subjects . Moreover, Zn2+ supplementation greatly delays hippocampus-dependent memory deficits and strongly reduces both Aβ and tau pathology in the hippocampus of an AD mouse model .
However, distinct mechanisms might contribute to the observed decreases in PSD scaffold proteins in a brain region specific manner. In cortical cultures, the Aβ1-40-mediated reduction of PSD-95 protein levels is dependent on NMDAR activity and cyclin-dependent kinase 5, involving the proteasomal pathway . However, the decreased levels of Homer1b and Shank1 were not influenced by proteasome activity. The decreased levels of synaptic Homer1b required de novo protein synthesis and involved the PI3-K pathway and calcineurin phosphatase (PP2B) activity, whereas declustering of Shank1 required NMDAR activity and activation of the ERK pathway . In this study, the focus on the hippocampal region and the use of primary cultured neurons derived from hippocampus might explain the differences in regulatory pathways and kinetics mediating decreased levels of PSD scaffold proteins. This is underlined by our results, showing that a downregulation of ProSAP2/Shank3 and Shank1 in cortical neuronal cultures indeed occurs already after 1 h treatment with Aβ as reported previously . Given that the hippocampus is the brain region with the highest Zn2+ concentration, Zn2+-dependent regulatory mechanisms of PSD plasticity might be more pronounced in the hippocampus compared to other brain regions.
Although sporadic forms of AD are the most common, mutations in presenilin are associated with familial AD causing approximately 50% of these cases. In fact, it was recently reported that presenilin is important for cellular copper and zinc turnover, having the potential to affect Aβ aggregation indirectly through metal ion clearance . Moreover, inflammatory processes that have been associated with AD  lead to a dysregulation of metallothioneins that might additionally sequester Zn2+. Thus, our experiments provide additional evidence for a common mechanism of the pathology of AD caused by the dysregulation of Zn2+ levels within the brain.
Based on our results and on recent studies , we conclude that Aβ complexes are able to bind extracellular and possibly also intracellular Zn2+, causing a dysregulation of Zn2+-dependent postsynaptic ProSAP/Shank scaffold proteins. Since ProSAP/Shank family members have specific roles in synapse formation and Shank1 is only targeted to a sufficiently preformed ProSAP1/Shank2-ProSAP2/Shank3 scaffold , the synaptic loss of ProSAP2/Shank3 could lead to instable synapse formation and/or maturation. This could further ultimately result in the untimely elimination of synapses [17, 27] as evidenced by a reduction of Shank1 at the PSD in Aβ treated neurons and in patients with AD. In terms of cognitive performance, this is expected to affect the establishment of new memory and the retention of older memories during disease progression.
Although the idea, that sequestration of Zn2+ by Aβ might cause the deficits seen in AD has been raised in the past, our data provide the first mechanistic insights, that could ty the dysregulation of a major postsynaptic scaffold molecule to the depletion of Zn2+ by Aβ and consecutive synapse elimination.
Chemicals and reagents
Zinquin ethyl ester, ZnCl2, the Zn2+ chelators CaEDTA and TPEN (N,N,N',N'-tetrakis(2-pyridylmethyl)-ethylenediamine) were purchased from Sigma-Aldrich. Zinpyr-1 was purchased from Mellitech. Primary antibodies were purchased from Covance (β-III Tubulin), Synaptic Systems (Homer1, PSD-95, VGluT), Novus Biologicals (Shank1 for IF), Stressgen (Bassoon), Sigma (PSD-95 for IF, Shank1 for WB) and Millipore (Aβ1-40 and Aβ1-42). ProSAP2/Shank3 antibodies have been described previously . Secondary Alexa-coupled antibodies were from Invitrogen. Unless otherwise indicated, all other chemicals were obtained from Sigma.
Hippocampal cultures from rat brain
The preparation of hippocampal cultures was performed essentially as described previously . Cell culture experiments of hippocampal primary neurons from rat (embryonic day 18; E18) were performed as described previously . After preparation, hippocampal neurons were seeded on poly-L-lysine (0.1 mg/ml; Sigma) glass coverslips. Cells were grown in Neurobasal medium (Invitrogen), complemented with B27 supplement (Invitrogen), 0.5 mM L-Glutamine (Invitrogen) and 100 U/ml penicillin/streptomycin (Invitrogen) and maintained at 37°C in 5% CO2. All animal experiments were performed in compliance with the guidelines for the welfare of experimental animals issued by the Federal Government of Germany and the National Institutes of Health. All of the experiments were conducted in strict compliance with APLAC approved animal protocols from Stanford University (protocol 14607) and by the local ethics committee at Ulm University (ID Number: O.103).
For immunofluorescence, the primary cultures were fixed with 4% paraformaldehyde (PFA)/1.5% sucrose/1x PBS at 4°C for 20 min and processed for immunohistochemistry. After washing 3 × 5 min with 1x PBS at RT, blocking was performed with 0.5% cold fish gelatine (Sigma) and 0,1% ovalbumin (Sigma)/1x PBS for 30 min at RT and the cells were washed again 3 × 5 min with 1x PBS at RT, followed by the primary antibody at 4°C overnight. After a 3 × 5 min washing-step with 1x PBS, incubation with the second antibody coupled to Alexa488, Alexa568 or Alexa647 for 1 h followed. The cells were washed again in 1x PBS for 10 min and 5 min with ddH2O and mounted with Mowiol with or without DAPI (4',6-diamidino-2-phenylindole, for staining the nuclei) for fluorescence microscopy. Fluorescence images were obtained using an upright Axioscope microscope equipped with a Zeiss CCD camera (16 bits; 1280 × 1024 ppi) using the Axiovision software (Zeiss) or a spinning disk confocal microscope from Zeiss with MetaMorph (Universal Imaging) software.
Human brains from patients with different dementia severity were obtained from the autopsy service at the Department of Psychiatry from the University of Geneva, School of Medicine, Geneva, Switzerland. All procedures were reviewed and approved by the relevant Institutional Review Board and Ethics Committees. Details on the cases are provided in Table 1. Materials were fixed as full hemispheres in 4% paraformaldehyde for up to 6 weeks. Sections from hippocampal blocks were cut on a vibratome at a thickness of 50 μm and kept as free-floating series in PBS-azide at 4°C. For staining, sections were exposed to blocking solution, 10% BSA in 1x PBS for 1 h at room temperature and then incubated with the appropriate primary antibody in the blocking solution overnight at 4°C. The sections were washed with buffer and incubated with the secondary antibody (1:1000) in blocking solution for 1 h at room temperature. Afterwards, sections were mounted in VectaShield (Vector Laboratories) with DAPI for confocal fluorescence microscopy.
Animal studies were conducted in accordance with the National Institutes of Health guidelines for the use of experimental animals, and protocols were approved by the Institutional Animal Care and Use Committee. All mice were housed in an environment controlled for lighting (12-hour light/dark cycle), temperature, and humidity, with food and water available ad libidum. Male APP(swe)-PS1(dE9) mice, backcrossed for more than ten generations to a C57BL/6J background, were used for this study along with male non-transgenic littermates. At 3, 6, or 12 months of age, mice were deeply anesthetized and trans-cardially perfused with 0.9% saline. Brains were removed and fixed with 4% PFA in PBS for 24 h followed by immersion in 30% sucrose in PBS for more than two days. Coronal brain sections (40 μm) were prepared using a sliding microtome and used for immunostaining experiments as described above.
To obtain P2/S2 fractions from hippocampal cultures, DIV15 cells exposed to different compounds of interest for the indicated times, were harvested and homogenized in homogenization buffer (320 mM sucrose, 5 mM HEPES, pH 7.4) containing protease inhibitor mixture (Roche). Cell debris and nuclei were removed by centrifugation at 1000 × g for 15 min. The supernatant was spun for 20 min at 12.0000 × g resulting in supernatant S2 (soluble fraction) and pellet P2 (membrane-associated fraction). Protein concentration was determined by amidoblack analysis and samples were further separated by SDS-PAGE, Coomassie-stained or blotted onto PVDF membranes using standard protocols. Immunoreactivity was visualized using HRP-conjugated secondary antibodies (DakoCytomation) and the SuperSignal detection system (Rockford).
Treatment of hippocampal cells
Aβ1-40, Aβ1-42 (American Peptides), Aβ29-40 peptide (VWR International) and labeled Aβ1-40 (Aβ HiLyte Fluor™ 555-labeled, Anaspec) were prepared as described previously  and snap frozen at -20°C. As reported in several previous studies, the predominant aggregates in such preparations consist of low N-oligomers (mainly monomeric to tetrameric). Experiments were done with primary hippocampal neurons at DIV15-17 as indicated. Aliquots of Aβ were diluted in culture medium to a final concentration of 1 μM or 10 μM immediately before use.
To assess Aβ cell toxicity, hippocampal DIV15 neurons were treated with Aβ1-40 (Ctrl, +1 μM ZnCl2 or 1 μM CaEDTA), Aβ1-42 and Aβ29-40 for 48 h and fixed at time-points 0 h, 6 h, 24 h and 48 h. The number of cells per optic field was determined counting DAPI positive nuclei and the number of neurons assessed by MAP2 staining. The mean of five different fields of view was calculated for each condition and time-point.
Pictures and were taken from neuronal synapses of hippocampal neurons with an upright Axioscope microscope equipped with a Zeiss CCD camera and a spinning disk confocal microscope from Zeiss. Quantification of fluorescence data was performed using MetaMorph (Universal Imaging), Image J 1.44e for Macintosh, Axiovision and Noam Ziv's Openview software.
Statistical analysis in this paper was performed using Microsoft Excel for Macintosh and tested for significance using t tests followed by ANOVA with an α level of significance set at 0.05 (< 0.05*; < 0.01**; < 0.001***). For evaluation, fluorescent puncta positive for a presynaptic marker (Bassoon, VGluT) and postsynaptic marker (ProSAP2/Shank3, Shank1, Homer1, PSD-95) along primary and secondary dendrites within the field of view were counted. Additionally, grey values and the signal area of post- and presynaptic proteins were measured and the results for the different conditions were evaluated in a blinded comparison. Pictures were all taken with the same acquisition time.
Zinypr-1 was stored as a 5 M stock solution in DMSO at -20°C. For cell culture neurons, growth medium was discarded and the cells were washed three times with HBBS. Hippocampal sections were incubated with a solution of 5 μM Zinquin ethyl ester or Zinpyr-1 in HBSS for 30 min. Zinpyr-1 (C46H36Cl2N6O5, MW: 823.22 g*mol-1) is a membrane-permeant fluorescent sensor for Zn2+ with a high specificity and affinity for zinc (Kd = 0.7 ± 0.1 nM). Zinquin ethyl ester was stored as a 5 M stock solution in DMSO at -20°C. Hippocampal neurons were incubated with a solution of 25 μM Zinquin ethyl ester in HBSS for 20 min at 37°C .
Cos7 cell assay
Cos7 cells were maintained in Dulbecco's modified Eagle's medium (DMEM) with high glucose (Invitrogen), supplemented with 10% (v/v) fetal calf serum, 2 mM L-glutamine and 5 μM ZnCl2. Cells were grown on commercially available chamber-slides (Nunc) treated with poly-L-lysine (0.1 mg/ml; Sigma). Transfection experiments with GFP-ProSAP2 (aa1-1806; full-size ProSAP2/Shank3) were performed using the transfection-agent Lipofectamine 2000 (Invitrogen) according to the manufacturer's recommendations. At 16 h post-transfection, zinc-staining using Zinquin ethyl ester was performed (t = 0 min) or cells were treated for 10 min with TPEN (t = 10 min) followed by either zinc-staining or application of 10 μM fluorescent Aβ1-40 (β HiLyte Fluor™ 555-labeled) for 20 min. After application of fluorescent Aβ1-40, an equimolar amount of ZnCl2 (10 μM) was supplemented for 20 min and subsequently, zinc-staining (t = 50 min) was performed; Alternatively, 10 μM fluorescent Aβ preincubated for 1 h with 10 μM ZnCl2 was applied for 20 min followed by supplementation of 10 μM ZnCl2 for 20 min and subsequent zinc staining. After this, cells were fixed with 4% PFA and mounted in VectaShield without DAPI.
Quantitative Real-time PCR
Isolation of total RNA from primary neuronal cell cultures was performed using the RNeasy kit as described by the manufacturer. Isolated RNA was eluted in a total of 20 μl RNase-free water (supplied with the kit) and stored at -80°C.
For the reverse transcriptase-mediated PCR studies, first strand synthesis and real-time quantitative RT-PCR amplification were carried out in a one-step, single-tube format using the QuantiFast SYBR Green RT-PCR kit. Thermal cycling and fluorescent detection were performed using the Rotor-Gene-Q real-time PCR machine (model 2-Plex HRM) (Qiagen). The qRT-PCR was assayed in 0.1 ml strip tubes in a total volume of 20 μl reaction mixture containing 1 μl of undiluted total RNA, 2 μl of QuantiTect Primer Assay oligonucleotides, 10 μl of 2x QuantiFast SYBR Green RT-PCR Master Mix supplemented with ROX (5-carboxy-X-rhodamine) dye, 6.8 μl of RNase-free water (supplied with the kit) and 0.2 μl of QuantiFast RT Mix. RT. Amplification conditions were as follows: 10 min at 50°C and 5 min at 95°C, followed by 40 cycles of PCR for 10 s at 95°C for denaturation, 30 s at 60°C for annealing and elongation (one-step). During the extension real-time fluorescence measurements were recorded by the PCR machine, thus monitoring real-time PCR amplification by quantitative analysis of the fluorescence emission. The SYBR Green I reporter dye signal was measured against the internal passive reference dye (ROX) to normalize non-PCR-related fluctuations in fluorescence which occurs from reaction tube to reaction tube. Resulting data were analysed utilizing the hydroxymethylbilane synthase gene as an internal standard to normalize transcript levels. Cycle threshold (ct) values were calculated by the Rotor-Gene-Q Software (version 2.0.2). Cycle threshold values indicate the PCR cycle number at which the measured fluorescence of the indicator dye (SYBR Green I), accordant to the quantity of amplified PCR products, is increasing in a linear fashion above background. All qRT-PCR reactions were run in duplicates in three independent experiments and mean ct values for each reaction were taken into account for calculations of data analysis. To ascertain primer specificity a melting curve was obtained for the amplicon products to determine their melting temperatures. Melting curve was driven from 60°C to 95°C rising in 1°C steps while fluorescence was recorded continuously. For negative controls and to check for reagent contamination a complete reaction mixture was used in which the RNA sample was replaced by RNase-free water. Real-time quantitative PCR was carried out using oligonucleotides allowing to investigate expression of the following genes: Shank1 and ProSAP2/Shank3 (validated primer pairs, Quantitect primer assay, Qiagen). All consumables used for the extraction of total RNA and real-time PCR analysis were purchased from Qiagen.
Hamos JE, DeGennaro LJ, Drachman D: Synaptic loss in Alzheimer's disease and other dementias. Neurology. 1989, 39 (3): 355-361.
Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, Hansen LA, Katzman R: Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol. 1991, 30: 572-580. 10.1002/ana.410300410.
DeKosky ST, Scheff SW, Styren SD: Structural correlates of cognition in dementia: quantification and assessment of synapse change. Neurodegeneration. 1996, 5: 417-421. 10.1006/neur.1996.0056.
Selkoe D: Amyloid β protein precursor and the pathogenesis of Alzheimer's disease. Cell. 1989, 58: 611-612. 10.1016/0092-8674(89)90093-7.
Selkoe D: Physiological production of the β-amyloid protein and the mechanisms of Alzheimer's disease. Trends Neurosci. 1993, 16: 403-409. 10.1016/0166-2236(93)90008-A.
Sisodia SS, Price DL: Role of the beta-amyloid protein in Alzheimer's disease. FASEB J. 1995, 9: 366-370.
Pham E, Crews L, Ubhi K, Hansen L, Adame A, Cartier A, Salmon D, Galasko D, Michael S, Savas JN, Yates JR, Glabe C, Masliah E: Progressive accumulation of amyloid-beta oligomers in Alzheimer's disease and in amyloid precursor protein transgenic mice is accompanied by selective alterations in synaptic scaffold proteins. FEBS J. 2010, 277: 3051-3067. 10.1111/j.1742-4658.2010.07719.x.
Grabrucker AM, Schmeisser MJ, Schoen M, Boeckers TM: Postsynaptic ProSAP/Shank scaffolds in the cross-hair of synaptopathies. Trends Cell Biol. 2011.
Durand CM, Betancur C, Boeckers TM, Bockmann J, Chaste P, Fauchereau F, Nygren G, Rastam M, Gillberg IC, Anckarsäter H, Sponheim E, Goubran-Botros H, Delorme R, Chabane N, Mouren-Simeoni MC, de Mas P, Bieth E, Rogé B, Héron D, Burglen L, Gillberg C, Leboyer M, Bourgeron T: Mutations in the gene encoding the synaptic scaffolding protein SHANK3 are associated with autism spectrum disorders. Nat Genet. 2007, 39 (1): 25-27. 10.1038/ng1933.
Moessner R, Marshall CR, Sutcliffe JS, Skaug J, Pinto D, Vincent J, Zwaigenbaum L, Fernandez B, Roberts W, Szatmari P, Scherer SW: Contribution of SHANK3 mutations to autism spectrum disorder. Am J Hum Genet. 2007, 81 (6): 1289-1297. 10.1086/522590.
Gauthier J, Champagne N, Lafrenière RG, Xiong L, Spiegelman D, Brustein E, Lapointe M, Peng H, Côté M, Noreau A, Hamdan FF, Addington AM, Rapoport JL, Delisi LE, Krebs MO, Joober R, Fathalli F, Mouaffak F, Haghighi AP, Néri C, Dubé MP, Samuels ME, Marineau C, Stone EA, Awadalla P, Barker PA, Carbonetto S, Drapeau P, Rouleau GA: De novo mutations in the gene encoding the synaptic scaffolding protein SHANK3 in patients ascertained for schizophrenia. Proc Natl Acad Sci USA. 2010, 107 (17): 7863-7868. 10.1073/pnas.0906232107.
Gong Y, Lippa CF, Zhu J, Lin Q, Rosso AL: Disruption of glutamate receptors at Shank-postsynaptic platform in Alzheimer's disease. Brain research. 2009, 1292: 191-198.
Roselli F, Hutzler P, Wegerich Y, Livrea P, Almeida OF: Disassembly of shank and homer synaptic clusters is driven by soluble beta-amyloid(1-40) through divergent NMDAR-dependent signalling pathways. PLoS one. 2009, 4 (6): 6011-10.1371/journal.pone.0006011.
Roselli F, Tirard M, Lu J, Hutzler P, Lamberti P, Livrea P, Morabito M, Almeida OF: Soluble beta-amyloid1-40 induces NMDA-dependent degradation of postsynaptic density-95 at glutamatergic synapses. J Neurosci. 2005, 25 (48): 11061-11070. 10.1523/JNEUROSCI.3034-05.2005.
Roselli F, Livrea P, Almeida OF: CDK5 is essential for soluble amyloid β-induced degradation of GKAP and remodeling of the synaptic actin cytoskeleton. PLoS one. 2011, 6 (7): 23097-10.1371/journal.pone.0023097.
Baron MK, Boeckers TM, Vaida B, Faham S, Gingery M, Sawaya MR, Salyer D, Gundelfinger ED, Bowie JU: An architectural framework that may lie at the core of the postsynaptic density. Science. 2006, 311 (5760): 531-535. 10.1126/science.1118995.
Grabrucker AM, Knight MJ, Proepper C, Bockmann J, Joubert M, Rowan M, Nienhaus GU, Garner CC, Bowie JU, Kreutz MR, Gundelfinger ED, Boeckers TM: Concerted action of zinc and ProSAP/Shank in synaptogenesis and synapse maturation. EMBO J. 2011, 30 (3): 569-581. 10.1038/emboj.2010.336.
Gundelfinger ED, Boeckers TM, Baron MK, Bowie JU: A role for zinc in postsynaptic density asSAMbly and plasticity?. Trends Biochem Sci. 2006, 31 (7): 366-373. 10.1016/j.tibs.2006.05.007.
Frederickson CJ, Bush AI: Synaptically released zinc: physiological functions and pathological effects. Biometals. 2001, 14 (3-4): 353-366.
Lee JY, Mook-Jung I, Koh JY: Histochemically reactive zinc in plaques of the Swedish mutant beta-amyloid precursor protein transgenic mice. J Neurosci. 1999, 19 (11): RC10-
Lovell MA, Robertson JD, Teesdale WJ, Campbell JL, Markesbery WR: Copper, iron and zinc in Alzheimer's disease senile plaques. J Neurol Sci. 1998, 158 (1): 47-52. 10.1016/S0022-510X(98)00092-6.
Suh SW, Jensen KB, Jensen MS, Silva DS, Kesslak PJ, Danscher G, Frederickson CJ: Histochemically-reactive zinc in amyloid plaques, angiopathy, and degenerating neurons of Alzheimer's diseased brains. Brain Res. 2000, 852 (2): 274-278. 10.1016/S0006-8993(99)02096-X.
Atwood CS, Scarpa RC, Huang X, Moir RD, Jones WD, Fairlie DP, Tanzi RE, Bush AI: Characterization of copper interactions with alzheimer amyloid beta peptides: identification of an attomolar-affinity copper binding site on amyloid beta1-42. J Neurochem. 2000, 75 (3): 1219-1233.
Bush AI, Pettingell WH, Multhaup G, d. Paradis M, Vonsattel JP, Gusella JF, Beyreuther K, Masters CL, Tanzi RE: Rapid induction of Alzheimer Abeta amyloid formation by zinc. Science. 1994, 265 (5177): 1464-1467. 10.1126/science.8073293.
Miller Y, Ma B, Nussinov R: Zinc ions promote Alzheimer Abeta aggregation via population shift of polymorphic states. Proc Natl Acad Sci USA. 2010, 107 (21): 9490-9495. 10.1073/pnas.0913114107.
Boeckers TM, Kreutz MR, Winter C, Zuschratter W, Smalla KH, Sanmarti-Vila L, Wex H, Langnaese K, Bockmann J, Garner CC, Gundelfinger ED: Proline-rich synapse-associated protein-1/cortactin binding protein 1 (ProSAP1/CortBP1) is a PDZ-domain protein highly enriched in the postsynaptic density. J Neurosci. 1999, 19 (15): 6506-6518.
Sala C, Piëch V, Wilson NR, Passafaro M, Liu G, Sheng M: Regulation of dendritic spine morphology and synaptic function by Shank and Homer. Neuron. 2001, 31 (1): 115-130. 10.1016/S0896-6273(01)00339-7.
Coyle P, Zalewski PD, Philcox JC, Forbes IJ, Ward AD, Lincoln SF, Mahadevan I, Rofe AM: Measurement of zinc in hepatocytes by using a fluorescent probe, zinquin: relationship to metallothionein and intracellular zinc. Biochem J. 1994, 303 (3): 781-786.
Yang DS, McLaurin J, Qin K, Westaway D, Fraser PE: Examining the zinc binding site of the amyloid-beta peptide. Eur J Biochem. 2000, 267 (22): 6692-6698.
Talmard C, Bouzan A, Faller P: Zinc binding to amyloid-beta: isothermal titration calorimetry and Zn competition experiments with Zn sensors. Biochemistry. 2007, 46 (47): 13658-13666. 10.1021/bi701355j.
Danielsson J, Pierattelli R, Banci L, Gräslund A: High-resolution NMR studies of the zinc-binding site of the Alzheimer's amyloid beta-peptide. FEBS J. 2007, 274 (1): 46-59. 10.1111/j.1742-4658.2006.05563.x.
Lacor PN, Buniel MC, Furlow PW, Clemente AS, Velasco PT, Wood M, Viola KL, Klein WL: Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. J Neurosci. 2007, 27: 796-807. 10.1523/JNEUROSCI.3501-06.2007.
Kodali R, Williams AD, Chemuru S, Wetzel R: Abeta(1-40) forms five distinct amyloid structures whose beta-sheet contents and fibril stabilities are correlated. J Mol Biol. 2010, 401 (3): 503-517. 10.1016/j.jmb.2010.06.023.
Selkoe DJ: Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior. Behav Brain Res. 2008, 192: 106-113. 10.1016/j.bbr.2008.02.016.
Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, Morgan TE, Rozovsky I, Trommer B, Viola KL, Wals P, Zhang C, Finch CE, Krafft GA, Klein WL: Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA. 1998, 95: 6448-6453. 10.1073/pnas.95.11.6448.
Klein WL, Krafft GA, Finch CE: Targeting small Abeta oligomers: the solution to an Alzheimer's disease conundrum?. Trends Neurosci. 2001, 24: 219-224. 10.1016/S0166-2236(00)01749-5.
Walsh DM, Selkoe DJ: Oligomers on the brain: the emerging role of soluble protein aggregates in neurodegeneration. Protein Pept Lett. 2004, 11: 213-228. 10.2174/0929866043407174.
Klyubin I, Betts V, Welzel AT, Blennow K, Zetterberg H, Wallin A, Lemere CA, Cullen WK, Peng Y, Wisniewski T, Selkoe DJ, Anwyl R, Walsh DM, Rowan MJ: Amyloid beta protein dimer-containing human CSF disrupts synaptic plasticity: prevention by systemic passive immunization. J Neurosci. 2008, 28: 4231-4237. 10.1523/JNEUROSCI.5161-07.2008.
Bush AI, Pettingell WH, Paradis MD, Tanzi RE: Modulation of Abeta adhesiveness and secretase site cleavage by zinc. J Biol Chem. 1994, 269 (16): 12152-12158.
Matsubara T, Hiura Y, Kawahito O, Yasuzawa M, Kawashiro K: Selection of novel structural zinc sites from a random peptide library. FEBS Lett. 2003, 555 (2): 317-321. 10.1016/S0014-5793(03)01266-3.
Adlard PA, Parncutt JM, Finkelstein DI, Bush AI: Cognitive loss in zinc transporter-3 knock-out mice: a phenocopy for the synaptic and memory deficits of Alzheimer's disease?. J Neurosci. 2010, 30 (5): 1631-1636. 10.1523/JNEUROSCI.5255-09.2010.
Cole TB, Wenzel HJ, Kafer KE, Schwartzkroin PA, Palmiter RD: Elimination of zinc from synaptic vesicles in the intact mouse brain by disruption of the ZnT3 gene. Proc Natl Acad Sci USA. 1999, 96 (4): 1716-1721. 10.1073/pnas.96.4.1716.
Deshpande A, Kawai H, Metherate R, Glabe CG, Busciglio J: A Role for Synaptic Zinc in Activity-Dependent Aβ Oligomer Formation and Accumulation at Excitatory Synapses. J Neurosci. 2009, 29 (13): 4004-4015. 10.1523/JNEUROSCI.5980-08.2009.
Gylys KH, Fein JA, Yang F, Wiley DJ, Miller CA, Cole GM: Synaptic changes in Alzheimer's disease: increased amyloid-beta and gliosis in surviving terminals is accompanied by decreased PSD-95 fluorescence. Am J Pathol. 2004, 165: 1809-1817. 10.1016/S0002-9440(10)63436-0.
Koffie RM, Meyer-Luehmann M, Hashimoto T, Adams KW, Mielke ML, Garcia-Alloza M, Micheva KD, Smith SJ, Kim ML, Lee VM, Hyman BT, Spires-Jones TL: Oligomeric amyloid beta associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques. Proc Natl Acad Sci USA. 2009, 106: 4012-4017. 10.1073/pnas.0811698106.
Sze CI, Troncoso JC, Kawas C, Mouton P, Price DL, Martin LJ: Loss of the presynaptic vesicle protein synaptophysin in hippocampus correlates with cognitive decline in Alzheimer disease. J Neuropathol Exp Neurol. 1997, 56 (8): 933-944. 10.1097/00005072-199708000-00011.
Zhan SS, Beyreuther K, Schmitt HP: Quantitative assessment of the synaptophysin immuno-reactivity of the cortical neuropil in various neurodegenerative disorders with dementia. Dementia. 1993, 4 (2): 66-74.
Viola KL, Velasco PT, Klein WL: Why Alzheimer's is a disease of memory: the attack on synapses by A beta oligomers (ADDLs). J Nutr Health Aging. 2008, 12: 51-57. 10.1007/BF02982587.
Kandimalla KK, Scott OG, Fulzele S, Davidson MW, Poduslo JF: Mechanism of neuronal versus endothelial cell uptake of Alzheimer's disease amyloid beta protein. PLoS One. 2009, 4 (2): e4627-10.1371/journal.pone.0004627.
Lai AY, McLaurin J: Mechanisms of amyloid-Beta Peptide uptake by neurons: the role of lipid rafts and lipid raft-associated proteins. Int J Alzheimers Dis. 2010, 2011: 548380-
LaFerla FM, Green KN, Oddo S: Intracellular amyloid-beta in Alzheimer's disease. Nat Rev Neurosci. 2007, 8 (7): 499-509. 10.1038/nrn2168.
Mocchegiani E, Malavolta M: Zinc dyshomeostasis, ageing and neurodegeneration: implications of A2M and inflammatory gene polymorphisms. J Alzheimers Dis. 2007, 12 (1): 101-109.
Carrasco J, Adlard P, Cotman C, Quintana A, Penkowa M, Xu F, Van Nostrand WE, Hidalgo J: Metallothionein-I and -III expression in animal models of Alzheimer disease. Neuroscience. 2006, 143 (4): 911-922. 10.1016/j.neuroscience.2006.08.054.
Lyubartseva G, Smith JL, Markesbery WR, Lovell MA: Alterations of zinc transporter proteins ZnT-1, ZnT-4 and ZnT-6 in preclinical Alzheimer's disease brain. Brain Pathol. 2010, 20 (2): 343-350. 10.1111/j.1750-3639.2009.00283.x.
Zheng W, Wang T, Yu D, Feng WY, Nie YX, Stoltenberg M, Danscher G, Wang ZY: Elevation of zinc transporter ZnT3 protein in the cerebellar cortex of the AbetaPP/PS1 transgenic mouse. J Alzheimers Dis. 2010, 20 (1): 323-331.
Baum L, Chan IH, Cheung SK, Goggins WB, Mok V, Lam L, Leung V, Hui E, Ng C, Woo J, Chiu HF, Zee BC, Cheng W, Chan MH, Szeto S, Lui V, Tsoh J, Bush AI, Lam CW, Kwok T: Serum zinc is decreased in Alzheimer's disease and serum arsenic correlates positively with cognitive ability. Biometals. 2010, 23 (1): 173-179. 10.1007/s10534-009-9277-5.
Corona C, Masciopinto F, Silvestri E, Del Viscovo A, Lattanzio R, Sorda RL, Ciavardelli D, Goglia F, Piantelli M, Canzoniero LM, Sensi SL: Dietary zinc supplementation of 3xTg-AD mice increases BDNF levels and prevents cognitive deficits as well as mitochondrial dysfunction. Cell Death and Disease. 2010, 1: 1-8. 10.1038/cddis.2009.2.
Greenough MA, Volitakis I, Li QX, Laughton K, Evin G, Ho M, Dalziel AH, Camakaris J, Bush AI: Presenilins promote the cellular uptake of copper and zinc and maintain Cu-chaperone of sod1-dependent Cu/Zn superoxide dismutase activity. J Biol Chem. 2011.
Di Stefano A, Sozio P, Cerasa LS, Iannitelli A, Cataldi A, Zara S, Giorgioni G, Nasuti C: Ibuprofen and lipoic acid diamide as co-drug with neuroprotective activity: pharmacological properties and effects in beta-amyloid (1-40) infused Alzheimer's disease rat model. Int J Immunopathol Pharmacol. 2010, 2: 589-599.
Schmeisser MJ, Grabrucker AM, Bockmann J, Boeckers TM: Synaptic crosstalk betweeen N-methyl-D-aspartate receptors and LAPSER1-beta-catenin at excitatory synapses. J Biol Chem. 2009, 284 (42): 29146-29157. 10.1074/jbc.M109.020628.
MJS and PTU were supported by a thesis grant from Ulm University, International Graduate School Molecular Medicine. AMG was supported by a fellowship from the Deutsche Forschungsgemeinschaft (DFG) and the NIH (P01 NS053862; R21 MH091471 to CCG). PRH and JDB were supported by NIH grant P50 AG05138. KIH was supported by NIH grant R01 AG030209-01A2, TMB by the DFG (Bo 1718/3-1; SFB 497/B8). The authors thank Dr C. Bouras for generous provision of human brain materials and B. Wicinski for expert technical assistance.
The authors declare that they have no competing interests.
AMG and MJS designed the outline of this study and carried out all experiments in cell culture together with MS. MJS and PTU performed the biochemical and qRT-PCR analysis. AMG performed the staining of human and mouse brain sections. PRH provided human, KIA and NSW provided mouse-brain sections and participated with JDB and TMB in the design and coordination of the study. AMG and MJS performed all data analysis and jointly drafted the manuscript with MA, PRH, JDB, CCG and TMB. All authors read and approved the final version. AMG and MJS contributed equally to this study.
Andreas M Grabrucker, Michael J Schmeisser contributed equally to this work.
Electronic supplementary material
Additional file 1: 1-42 . Hippocampal neurons (DIV15) were treated with 1 μM Aβ1-42 (soluble oligomers) and fixed after 0, 6, and 24 h. Immunocytochemistry was performed using anti-ProSAP2/Shank3 with anti-Bassoon as presynaptic marker. Images were taken with the same acquisition time and the mean grey value and mean area of ProSAP/Shank signals opposite Bassoon signals was measured. A) The synapse density was calculated measuring the number of synapses per unit dendrite length of ten cells of three independent experiments for every time-point and condition. The ratio of the mean synapse density between treated and untreated neurons shows a significant decrease in synapse density starting at 6 h exposure to Aβ1-42. B) The ratio of mean grey values between treated and untreated neurons shows a significant downregulation of ProSAP2/Shank3 at the synapse after 24 h treatment with Aβ1-42. C) Cultured hippocampal neurons were immunostained with antibodies against Homer1 and PSD-95 and the ratio of mean grey values between treated and untreated neurons was measured after 0 h, 1 h and 24 h treatment with Aβ1-40. A significant decrease is seen after 24 h of treatment. D) The mean signal intensity of Homer1, ProSAP2/Shank3 or Shank1 signals opposite Bassoon puncta was measured at time-point 0 h, 1 h and 24 h after Aβ1-40-treatment of cortical neurons. The ratio of signal intensity between treated and untreated synapses is shown. A decrease of ProSAP2/Shank3 and Shank1 levels can be seen as early as 1 h after treatment. E) The mean area of ProSAP2/Shank3 or Shank1 signals opposite Bassoon puncta was measured after Aβ1-40-treatment. The change in the ratio of mean grey values per mean area between treated and untreated synapses (see Figure 1C) is based on a change in grey values, since the mean signal area is found to be the same for all time-points and conditions. The results show no significant changes between treated and untreated neurons. F) ProSAP2/Shank3 levels in immature vs. mature spines was measured using fluorescence grey values after 24 h Aβ1-40 treatment and compared to control conditions (24 h treatment with DMSO). Fluorescence grey values were normalized against presynaptic marker (Bassoon) grey values. Immature synapses show lower levels of ProSAP2/Shank3, increasing from filopodia-like to thin and mushroom/stubby spines. Treatment with Aβ1-40 significantly decreases the amount of ProSAP2/Shank3 in all spine types (significance indicated for comparison between "filopodia like" and "filopodia like after treatment", "thin" and "thin after treatment" etc.). (TIFF 1 MB)
Additional file 2: 1-40 treatment. A) Western blots of S2 soluble fractions from hippocampal neurons cultured for 15 DIV and then treated for 6 h and 24 h with Aβ1-40 (P2 fractions presented in Figure 2A). Compared to untreated cells at time-point 0, no decrease in the amount of ProSAP2/Shank3 and Shank1 could be detected after 6 h or 24 h of Aβ-treatment. Note, Homer1 and PSD-95 levels did not change. Lysates from 3 independent experiments were quantified via Western Blot analysis by measuring the integrated density. The values were normalized against β-III Tubulin and 0 h was set to 100%. B) The reduction of ProSAP2/Shank3 and Shank1 at the synapse is independent of both, proteasomal degradation and protein synthesis, since treatment with the proteasome inhibitor MG132 and protein synthesis inhibitor CHX did not prevent Aβ1-40 induced changes in synaptic signal intensities of ProSAP2/Shank3 and Shank1. MK801, a NMDAR antagonist showed a tendency to prevent Aβ1-40 induced changes in ProSAP2/Shank3 (although statistically not significant), but significantly decreased the amount of Aβ1-40 induced changes in Shank1 levels. The ratio between two sets of untreated control cells is shown and compared to the ratio between cells treated with Aβ and untreated cells as well as cells treated with MG132, CHX or MK801 in presence of Aβ and cells treated with MG132, CHX or MK801 alone. (TIFF 1 MB)
Additional file 3: 1-40 . A) Zinquin ethyl ester detects synaptic Zn2+ signals. Co-labeling with FM dye reveals that the Zn2+ staining is mostly opposed to FM, thus marking postsynaptic compartments. B) After treatment of hippocampal neurons with 1 μM and 10 μM Aβ1-40, a reduction in dendritic Zn2+ signal area above a fixed fluorescent threshold can be seen. The mean area of Zinquin signals above a fluorescence limit was measured from five cells and the ratio between cells treated for 6 or 24 h and untreated cells is shown. A significant reduction can be seen after 6 h (10 μM) and 24 h (10 μM) treatment. (TIFF 941 KB)
Additional file 4: in vitro. A) Coomassie staining, showing that similar amounts of protein were loaded for the quantification of changes in synaptic protein levels by Western blot analysis presented in Figure 5E. B-D) Hippocampal neurons (DIV15) were treated with 1 μM Aβ29-40 and fixed after 0, 6, and 24 h. Immunocytochemistry was performed using anti-ProSAP2/Shank3 with anti-Bassoon as presynaptic marker. Images were taken with the same acquisition time and the mean grey value and mean area of ProSAP/Shank signals opposite Bassoon signals was measured. B) Effect of Aβ and Zn2+ on ProSAP2/Shank3 levels are independent of protein synthesis. Cultured hippocampal neurons were immunostained with antibodies against ProSAP2/Shank3 and the ratio of mean grey values between treated and untreated neurons was measured after 24 h treatment with Aβ1-40 or Aβ1-40 with equimolar ZnCl2 supplementation (see Figure 5) with and without application of the protein synthesis inhibitor CHX (15 μM). The presence of CHX does not prevent rescue of ProSAP2/Shank3 levels by ZnCl2 supplementation. C) Cultured hippocampal neurons (DIV 15) were immunostained with antibodies against Shank1 and Homer1 and the ratio of mean grey values between treated and untreated neurons was measured after 24 h treatment with Aβ1-40 or Aβ1-40 with equimolar ZnCl2 supplementation (see Figure 5). ZnCl2 supplementation leads to a significant increase in Shank1 signal intensity at the synapse. Although Homer1 levels are also increased, there is still a significant difference to control cells and no statistically significant difference to Aβ treated cells. D) The synapse density was calculated measuring the number of synapses per unit dendrite length of ten cells of three independent experiments for every time-point and condition. The ratio of the mean synapse density between treated and untreated neurons shows no significant decrease in synapse density. E) The ratio of mean grey values between treated and untreated neurons shows no significant downregulation of ProSAP2/Shank3 at the synapse after 24 h treatment with Aβ29-40. F) Hippocampal neurons (DIV15) were treated with Aβ1-40 Aβ1-42 and Aβ29-40 and fixed after 0, 6, and 24 h. The number of cells per optic field was identified by DAPI staining of nuclei and labeling of neurons by MAP2. No significant reduction is seen after 24 h (magnification of typical field of view of Aβ1-40 treated neurons, right panel) (scale bar = 200 μm). G) However, after 48 h, Aβ1-40 Aβ1-42 and Aβ29-40 treated neurons show signs of cell death (arrows, magnification of typical field of view of Aβ1-40 treated neurons, right panel). Supplementation of cultures with 1 μM ZnCl2 or zinc depletion using the cell impermeable Zn2+ chelator CaEDTA did not lead to any changes in the amount of cell death (scale bar = 200 μm). (TIFF 2 MB)
Additional file 5: . Zn2+ ions were visualized by Zinpyr-1 in human (and mouse, data not shown) brain sections and the fluorescence of intracellular Zn2+ staining measured in control sections with and without application of TPEN prior to Zn2+ staining. The fluorescence of the Zinpyr-1 dye is mostly absent in TPEN-treated section revealing the high specificity of the Zn2+-staining in brain sections. (TIFF 2 MB)
Additional file 6: . Zn2+ ions were visualized by Zinpyr-1 and the fluorescence of intracellular Zn2+ staining measured in APP-PS1 mouse hippocampal brain sections from dentate gyrus (dg) and CA3 region in mice 3, 6 and 12 m.o.a (Inset on the upper right: p = pyramidal cells, g = granule cells). (TIFF 10 MB)
Authors’ original submitted files for images
Below are the links to the authors’ original submitted files for images.
About this article
Cite this article
Grabrucker, A.M., Schmeisser, M.J., Udvardi, P.T. et al. Amyloid beta protein-induced zinc sequestration leads to synaptic loss via dysregulation of the ProSAP2/Shank3 scaffold. Mol Neurodegeneration 6, 65 (2011). https://doi.org/10.1186/1750-1326-6-65
- Alzheimer's disease